Biotech - Spark Newswire

2 minute read

Curis To Host Virtual Event To Discuss Updated Clinical Data For CA-4948 In AML/MDS Presented At EHA

Today, 6:53 PM

Curis, Inc. (NASDAQ:CRIS), a biotechnology company focused on the development of innovative therapeutics for the treatment of cancer, today announced that it will host a virtual KOL event to discuss progress to date for

CRIS

1 minute read

FDA
News

Zynerba Highlights Poster Presentation At Associated Professional Sleep Societies SLEEP 2021 Annual Meeting Jun. 11

By Benzinga Newsdesk

Today, 6:53 PM

Zynerba Pharmaceuticals, Inc. (NASDAQ:ZYNE), the leader in innovative pharmaceutically-produced transdermal cannabinoid therapies for rare and near-rare neuropsychiatric disorders, today announced the acceptance and

ZYNE

2 minute read

FDA
News

Intellia Therapeutics Highlights Will Present Interim Clinical Data From Ongoing Phase 1 Study Of NTLA-2001 For Treatment Of Transthyretin Amyloidosis at the 2021 Peripheral Nerve Society Annual Meeting Jun. 26

By Benzinga Newsdesk

Today, 6:53 PM

Data to offer insight into safety and pharmacodynamics of NTLA-2001, the first-ever systemically administered in vivo CRISPR therapy candidate Late-breaking abstract selected for oral presentation on June

NTLA

1 minute read

AstraZeneca, Merck Lynparza Earns Win in Early Breast Cancer, Showing Potential in Post-Surgery Setting

By Vandana Singh

Today, 6:53 PM

AstraZeneca Plc (NASDAQ:AZN) and Merck & Co Inc (NYSE:MRK) have announced the first presentation of data from the Phase 3 OlympiA trial evaluating…

AZN

1 minute read

Merck’s Keytruda Shows Clinical Benefit in Post-Surgery Kidney Cancer Setting

By Vandana Singh

Today, 6:53 PM

Merck & Co (NYSE:MRK) announced first-time results from the pivotal Phase 3 KEYNOTE-564 trial evaluating Keytruda for the potential adjuvant treatment…

MRK

2 minute read

FDA
News

Virios Therapeutics Reports First Patient Dosed In P hase 2b Trial Evaluating IMC-1 In Patients with Fibromyalgia

By Benzinga Newsdesk

Today, 6:53 PM

Virios Therapeutics, Inc. (Nasdaq: VIRI), a clinical-stage biotechnology company focused on advancing novel antiviral therapies to treat diseases associated with virally triggered or maintained immune responses,

VIRI

2 minute read

FDA
News

Imara To Present Clinical Data On IMR-687 In Sickle Cell Disease At European Hematology Association Congress Jun. 15 At 10 a.m. EDT

By Benzinga Newsdesk

Today, 6:53 PM

Oral presentation provides final results from 93-patient Phase 2a trial and additional interim data from open label extension trial Imara to host conference call and live webcast on June 11, 2021 at 8:00 a.m.

IMRA

1 minute read

FDA
News

Surface Oncology Reports Collaboration With Roche To Evaluate Co.’s Investigational Anti-IL-27 Antibody In Combo With Roche’s Atezolizumab, Bevacizumab In Patients With Treatment-Naïve Hepatocellular Carcinoma

By Benzinga Newsdesk

Today, 6:53 PM

Surface Oncology (NASDAQ:SURF), a clinical-stage immuno-oncology company developing next-generation immunotherapies that target the tumor microenvironment, today announced a clinical trial collaboration with Roche

SURF

3 minute read

FDA
News

BeyondSpring Reports First Patient Dosed In Triple-Combo Study With Plinabulin, PD-1/PD-L1 Inhibitor, Radiotherapy For Reversal of Resistance to PD-1/PD-L1 Inhibitors in Patients with Advanced Solid Tumors

By Benzinga Newsdesk

Today, 6:53 PM

Resistance to immunotherapy is a severe unmet medical need that plinabulin aims to address in combination with checkpoint inhibitors and radiotherapy First patient who failed Keytruda and chemotherapy has been dosed

BYSI

6 minute read

FDA
News

Fate Therapeutics Reports Interim Data From Phase 1 Study Of FT516 In Combo With Rituximab For B-Cell Lymphoma At American Society Of Clinical Oncology

By Benzinga Newsdesk

Today, 6:53 PM

8 of 11 Patients in Dose Escalation Cohorts 2 and 3 Achieved Objective Response 6 of 11 Patients Achieved Complete Response, including 2 Patients Previously Treated with Autologous CD19 CAR T-cell Therapy Favorable

FATE